Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
about
Cancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesisEfficacy and safety of tenofovir in chronic hepatitis B: Australian real world experienceVirus-related liver cirrhosis: molecular basis and therapeutic options.A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial.Use of serum levels of proinflammatory cytokine IL-1alpha in chronic hepatitis B.Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expressionAn observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal.Phosphatase and tensin homologue genetic polymorphisms and their interactions with viral mutations on the risk of hepatocellular carcinoma.Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.Lamivudine Resistance and Precore Variants in Iranian Patients With Chronic Hepatitis B: Correlation With Virological and Clinical Features.Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects.Insulin receptor substrate-4 interacts with ubiquitin-specific protease 18 to activate the Jak/STAT signaling pathway.Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection.
P2860
Q26766386-6E5223BC-EA18-448B-91AE-78D7A38A8399Q28468387-6F350B93-4058-4964-B669-8EB8F1CF0F87Q33718267-AAE5E4B5-C6D5-43D2-9FEE-04386FDEE8FCQ33933196-53FDF25B-7469-471D-8778-2E13C97B0C5FQ34528429-2768DD7F-36DB-4512-B6AA-34B7223F8D6BQ34746406-72B1A82F-3A00-4B05-9C70-1F68B9231233Q35126674-D0E444C4-586A-4899-82E5-9C633D53CE88Q35914175-F9CB6A03-90ED-480F-8833-B775DAE11638Q36801410-DE5B36DC-378C-4C45-BF7D-42576479F5B7Q37629064-76BE4F12-4FA3-445E-87EA-58900F7621E2Q41197606-D731B515-CAE4-4188-8DE1-892F8CD6BBAEQ42386335-5EDC7946-CD16-4815-863B-855BDDDFCC2BQ47120705-166988FF-E227-48F8-83D9-49ED9121244CQ47253648-2FF55466-F6F3-43AA-B6F3-A54C4F3F21FCQ55422383-AC329900-4051-4D17-A174-F01C4410CA17
P2860
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
@en
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
@nl
type
label
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
@en
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
@nl
prefLabel
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
@en
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
@nl
P2093
P2860
P356
P1476
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.
@en
P2093
Guang-Wen Cao
Hong-Wei Zhang
Li-Ping Chen
Yi-Fang Han
P2860
P304
P356
10.5501/WJV.V1.I6.174
P50
P577
2012-12-01T00:00:00Z